Sue Dillon, Ph.d.

Biography

 Sue Dillon, Ph.D. has end-to-end responsibility for immunology drug discovery, biomarkers, translational medicine, clinical development and life cycle management for a number of industry-leading products. She leads a global team focused on combining internal and external innovation approaches to discover and develop new solutions for patients with serious autoimmune diseases. Sue is also responsible for management of the Janssen Human Microbiome Institute, Covagen LLC and Janssen Immunosciences.  An experienced leader in R&D, Sue has held senior positions at large pharmaceutical companies and biotechs. Sue joined the Johnson & Johnson Family of Companies as Vice President, Centocor R&D Discovery Research in 2001 and has held positions of increasing responsibility leading to her 2009 appointment to her current role as Global Therapeutic Area Head for Immunology. During her tenure, the Immunology Therapeutic Area has continued to build a strong immunology portfolio and pipeline of innovative assets in early development and discovery.  Sue earned her Ph.D. in Microbiology and Immunology from Thomas Jefferson University, Philadelphia, Pennsylvania. She completed a National Institutes of Health (NIH)-sponsored postdoctoral fellowship in Immunology at Duke University, has published more than 50 scientific articles, and is inventor on three issued patents. In 2007, Sue was awarded the Distinguished Alumni Award from Thomas Jefferson University, and in 2013 Sue was selected by FierceBiotech as one of the “Top Women in Biotech”. Sue has served on the Board of Trustees of Bryn Mawr Hospital, and is currently on the Board of The Wistar Institute in Philadelphia.

Research Interest

 immunology